A nurse is reinforcing teaching with a client who is pregnant and has a prescription for Rho (D) immune globulin. Which of the following information should the nurse include?

Choice A rationale This medication works by suppressing the immune response in Rh-negative individuals who are exposed to Rh-positive red blood cells. By administering exogenous IgG antibodies, it prevents the maternal immune system from recognizing the foreign D antigen. This prevents the primary immune response and the subsequent production of endogenous anti-D antibodies. This process is essential to prevent hemolytic disease of the newborn in future pregnancies where the fetus may be Rh-positive. Choice B rationale The primary mechanism of Rho (D) immune globulin is directed at the maternal immune system rather than the fetal or newborn circulation. It does not provide active or passive immunity to the infant to prevent antibody formation within the child's own system. Instead, it ensures the mother does not produce antibodies that could cross the placenta. The newborn is not the recipient of the immune suppression provided by this specific prophylactic medical intervention. Choice C rationale This medication is a preventative measure and does not possess the pharmacological capability to destroy existing antibodies. Once antibodies are formed in the maternal circulation or passed to the newborn, Rho (D) immune globulin cannot neutralize or eliminate them. Management of a newborn with existing Rh antibodies involves different treatments such as exchange transfusions or phototherapy. The goal of this medication is strictly prophylaxis to avoid the initial sensitization of the Rh-negative mother. Choice D rationale Rho (D) immune globulin does not destroy existing maternal antibodies. If a woman is already sensitized, meaning her body has already produced anti-D antibodies, this medication is ineffective. It is designed to be administered to non-sensitized Rh-negative women at 28 weeks gestation and within 72 hours of delivery. It acts by clearing fetal Rh-positive cells from maternal circulation before the mother's immune system can react, not by destroying a pre-existing maternal antibody titer.